1692 related articles for article (PubMed ID: 18543257)
1. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
[TBL] [Abstract][Full Text] [Related]
2. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
3. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
4. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
6. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
7. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
8. Thapsigargin modulates osteoclastogenesis through the regulation of RANKL-induced signaling pathways and reactive oxygen species production.
Yip KH; Zheng MH; Steer JH; Giardina TM; Han R; Lo SZ; Bakker AJ; Cassady AI; Joyce DA; Xu J
J Bone Miner Res; 2005 Aug; 20(8):1462-71. PubMed ID: 16007343
[TBL] [Abstract][Full Text] [Related]
9. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.
Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K
Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161
[TBL] [Abstract][Full Text] [Related]
10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
[TBL] [Abstract][Full Text] [Related]
12. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
13. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
Park JY; Bae MA; Cheon HG; Kim SS; Hong JM; Kim TH; Choi JY; Kim SH; Lim J; Choi CH; Shin HI; Kim SY; Park EK
Biochem Biophys Res Commun; 2009 Jan; 378(3):645-9. PubMed ID: 19059209
[TBL] [Abstract][Full Text] [Related]
14. Evidence of reciprocal regulation between the high extracellular calcium and RANKL signal transduction pathways in RAW cell derived osteoclasts.
Xu J; Wang C; Han R; Pavlos N; Phan T; Steer JH; Bakker AJ; Joyce DA; Zheng MH
J Cell Physiol; 2005 Feb; 202(2):554-62. PubMed ID: 15389575
[TBL] [Abstract][Full Text] [Related]
15. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival.
Gingery A; Bradley E; Shaw A; Oursler MJ
J Cell Biochem; 2003 May; 89(1):165-79. PubMed ID: 12682917
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1).
Kwak HB; Jin HM; Ha H; Kang MJ; Lee SB; Kim HH; Lee ZH
Biochem Biophys Res Commun; 2005 May; 330(4):1080-6. PubMed ID: 15823554
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species mediate RANK signaling in osteoclasts.
Ha H; Kwak HB; Lee SW; Jin HM; Kim HM; Kim HH; Lee ZH
Exp Cell Res; 2004 Dec; 301(2):119-27. PubMed ID: 15530848
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.
Kwak HB; Lee SW; Li YJ; Kim YA; Han SY; Jhon GJ; Kim HH; Lee ZH
Biochem Pharmacol; 2004 Apr; 67(7):1239-48. PubMed ID: 15013839
[TBL] [Abstract][Full Text] [Related]
20. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
